Correction to: Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part I. Albumin-bound betulinic acid nanoparticles (ABBns)

This article refers to:

Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): part I. Albumin-bound betulinic acid nanoparticles (ABBns)

Srivari Y, Chatterjee P. (2016). Factors influencing the fabrication of albumin-bound drug nanoparticles (ABDns): Part I. Albumin-bound betulinic acid nanoparticles (ABBns). Journal of Microencapsulation. http://dx.doi.org/10.1080/02652048.2016.1222005.

When the above research articles was first published online:

1. Human serum albumin or HSA has been incorrectly mentioned as HAS in Table 4 and Table 5. Table 4 should read as

Table 4. Particle size analysis of BA-HSA complex in phosphate buffer at pH 7.4.

Surfactant	BA (μM)	HSA (μM)	[BA]/[HSA] Molar ratio	Particle size (D90%) nm	Zeta potential
Sodium cholate (0.5%, v/v)	18.75	75	0.25	10.0 ± 0.26	ND
Tween 20 (0.05%, v/v)	37.50	75	0.50	8.1 ± 0.32	ND
Sodium cholate (0.5%, v/v)	200	1500	∼0.13	11.7 ± 1.60	−35 mV^a

ND = Not Determined.

^a Average.

Table 5. Drug encapsulation efficiency for 200 μM BA at different concentration of HSA.

BA (μM)	HSA (%, v/v)	Molar ratio	Amount of BA bound to HSA (μg)	Drug encapsulation efficiency
200	20	∼0.05	84.03 ± 4.43	92 ± 4.85%
200	10	∼0.13	73.07 ± 4.15	80 ± 4.54%
200	5	∼0.25	45.67 ± 7.95	50 ± 8.70%

Table 5 should read as

2. Figure 5 has been incorrectly mentioned as Figure 6. Figure 5 should read as

Figure 5. Differential scanning calorimetry (DSC) thermograms of (a) neat betulinic acid (b) betulinic acid incubated for 24 h in water (stirred and dried) sample (c) betulinic acid incubated for 24 h in 0.1M phosphate buffer (stirred and dried) sample.

Figure 6. Cellular viability of neat BA and ABBns in A549 cells at 4 and 72 h time-period.

3. Figure 6 has been incorrectly mentioned as Figure 5. Figure 6 should read as

The authors apologise for the oversight.